Metraipolis › archive › dc_4bd72045f68f

Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer… — Europe PMC PMID:42428508

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42428508
DOI: 10.3389/fphar.2026.1811077
License (as archived): solo-consultazione
Archived: 2026-10-19T04:00:25.265Z
SHA-256 of the archived text: ad53603d9aa1af69dabc93f547d7fb79069bbbcc8d46b24020209e047f3fdc48
Stable URL of this page: https://metraipolis.com/documento/dc_4bd72045f68f

How to cite

Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer… — Europe PMC PMID:42428508 — Europe PMC (en), https://europepmc.org/article/MED/42428508 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4bd72045f68f (Metraipolis archive dc_4bd72045f68f, sha256 ad53603d9aa1af69dabc93f547d7fb79069bbbcc8d46b24020209e047f3fdc48)

BibTeX

@misc{dc4bd72045f68f,
  title = {Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer… — Europe PMC PMID:42428508},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42428508},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4bd72045f68f; sha256 ad53603d9aa1af69dabc93f547d7fb79069bbbcc8d46b24020209e047f3fdc48},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42428508. Agents can read the archived copy with the MCP tool read_document.